Medicine for the 21st century

In 2015, Zoe’s CSO, Dr. Douglas Vaughan, and collaborators identified a naturally occurring mutation in an Amish community that lowers PAI-1—the primary inhibitor of fibrinolysis and a key regulator of cellular senescence. Carriers live about ten years longer on average and exhibit lower rates of chronic disease than non-carriers. Guided by these human genetic insights, Zoe Biosciences is developing therapies targeting cardiometabolic aging across two drug programs: PAI-1 and APJ/apelin.